An Evidence-Grounded Intelligent Decision Support Information System for Predictive Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Manufacturing
- Department of Computer Science, University of New Haven, West Haven, CT
Abstract
The recurring detection of carcinogenic and potentially carcinogenic nitrosamine impurities in pharmaceutical products presents a significant challenge to public health, manufacturing quality, regulatory compliance, and pharmaceutical supply chain integrity. Although conventional analytical techniques, including liquid chromatography–tandem mass spectrometry (LC-MS/MS), provide essential capabilities for impurity detection and confirmation, they do not independently predict contamination across untested formulations and manufacturing conditions. This study presents an evidence-grounded intelligent decision support information system that integrates pharmaceutical chemistry, molecular feature engineering, predictive machine learning, mechanistic risk assessment, and quality management workflows for proactive nitrosamine risk identification. The proposed framework employs a four-tier architecture comprising chemical and environmental data acquisition, feature engineering and preprocessing, predictive risk modeling, and explainable engineering decision support. Relevant predictors include active pharmaceutical ingredient structures, nitrosatable amine characteristics, excipient nitrite concentrations, processing temperature, pH, moisture conditions, solvent recovery, and material genealogy. Candidate predictive algorithms include Random Forest, gradient-boosted decision trees, and graph neural networks, integrated with mechanistic formation assessment, carcinogenic potency categorization, purge evaluation, and acceptable intake calculations. The architecture translates predicted risks into traceable recommendations for analytical investigation, process optimization, excipient selection, and manufacturing quality control. A proposed validation framework incorporates experimental formation data, predictive accuracy, uncertainty assessment, and human oversight. The study contributes a unified information systems architecture for connecting chemical evidence with predictive analytics and lifecycle pharmaceutical risk governance, providing a foundation for future empirical implementation and validation.